SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following FDA approval of its oral Wegovy, making it the first GLP-1 pill for weight management. The community sees this as a major catalyst, providing a convenient alternative to injections and positioning Novo Nordisk with a crucial edge in the rapidly expanding obesity treatment market against rivals like Eli Lilly. Investors are closely watching its market impact.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust (SLV) is experiencing a powerful, near-parabolic rally to fresh all-time highs, fueled by escalating industrial demand from sectors like EV batteries and clean energy, alongside looming Chinese export restrictions tightening global supply. This has sparked intense debate among investors, with many anticipating a monumental short squeeze and continued price discovery, while others caution the asset is severely overbought and due for a significant pullback.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is trending as its merger target, Infleqtion, garners significant attention for its leadership in quantum sensing and defense applications, including recent partnerships with Safran and collaborations with NVIDIA. The community sees Infleqtion as a highly undervalued quantum play with real revenue and critical national security utility, anticipating a substantial re-rating post-merger as institutional capital flows in.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore Corp. (SOC) is actively trending following news of federal regulatory approval for its Las Flores Pipeline restart, shifting oversight from California to federal authority. This development is largely seen by the community as a significant de-risking event, fueling bullish sentiment and sparking discussions of a potential short squeeze given the stock's high short interest. Traders are anticipating substantial upside as this milestone paves the way for resuming offshore oil production.

Ascent Solar Technologies, Inc. engages in the design, development, and manufacture of solar technology and power solutions for remote locations and extreme environments. It integrates photovoltaic modules into a variety of applications such as aerospace, defense, transportation, and electronic products. The company was founded by Mohan S. Misra and Joseph H. Armstrong on October 18, 2005 and is headquartered in Thornton, CO.

Ascent Solar Technologies Inc

Ascent Solar Technologies is currently trending due to a series of recent teaming agreements and product evaluations for its advanced thin-film photovoltaic modules, specifically for space and defense applications. The community is highly engaged, with many anticipating significant contracts and long-term growth in the burgeoning space economy, while a skeptical contingent highlights historical issues of dilution and speculative trading patterns.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to recent reports of high-grade silver drill results from its exploration program, coinciding with a broader rally in precious metals prices. The community is actively discussing the potential for a short squeeze and significant long-term appreciation, especially given major investor Eric Sprott's continued share acquisitions. However, some cautionary voices highlight concerns about the stock's current valuation and the possibility of future share offerings.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is actively trending due to significant community discussion surrounding the federal reclassification of cannabis to Schedule III, an event widely seen as a major catalyst for the industry. The community is rallying behind tokens like $WEEDCOIN, leveraging Solana's high-speed network to champion a 'Green Revolution' aimed at disrupting pharmaceutical monopolies and attracting substantial capital on-chain. This strong narrative positions Solana as the preferred platform for this cultural and financial paradigm shift.

Starfighters Space Inc

Starfighters Space Inc. (FJET) is generating significant buzz due to extreme price volatility, fueling a fierce community debate. Bulls point to its low float and high shorting fees, anticipating a massive short squeeze, while skeptics warn of a pump-and-dump given its pre-revenue status and high market valuation. The ongoing battle between buyers and sellers, coupled with calls of market manipulation, keeps this aerospace-related ticker actively discussed.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies is garnering significant attention following a successful $20 million offering and key milestones, including graduating Shell's GameChanger program and validating its hydrochemolytic process for converting waste plastics into high-value oils. This has sparked a polarized community debate, with many investors highlighting these advancements and new partnerships as strong indicators of future growth in the circular plastics market. Conversely, skeptics question the company's valuation and economic viability at scale, despite the technological progress.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience (RGC) is attracting significant attention, fueled by its extremely low share float and substantial insider ownership, which is sparking community discussions about a potential short squeeze. Traders are actively tracking its high cost to borrow and anticipating a surge, drawing comparisons to its past explosive runs despite acknowledged speculative fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Salarius Pharmaceuticals (NASDAQ:SLRX) CFO Purchases $16,000.00 in Stock

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX - Get Free Report) CFO Mark Rosenblum purchased 20,000 shares of the company's stock in a transaction on Thursday, November 20th. The stock was purchased...

Penny Stocks To Follow Now - November 12th

Leap Therapeutics, Bitfarms, MSP Recovery, Strive, Salarius Pharmaceuticals, HIVE Digital Technologies, and Beyond Meat are the seven Penny stocks to watch today, according to MarketBeat's stock...

Why Did Salarius (SLRX) Shares Soar Over 23% After-Hours?

Salarius Pharmaceuticals shares jumped 23.7% in after-hours trading Tuesday, closing at $1.21 following its public offering announcement. read more...

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering PR Newswire HOUSTON, Nov...

Salarius Pharmaceuticals’ stock rose 5% after-hours on Monday after announcing it had regained full compliance with all Nasdaq listing requirements, removing the main hurdle to its planned merger with Decoy Therapeutics.The company said Nasdaq informed Salarius on Oct. 10 that it met the equity standard requirement, following an earlier notice in September that it had regained compliance with the minimum bid price rule.Nasdaq notified the company that it will remain under a one-year Mandatory Panel Monitor period through October 2026, during which any violation of equity standards could lead to a delisting notice and hearing process.The merger with Decoy Therapeutics, first announced in January and amended in September, will see Decoy merge into a unit of Salarius, with the combined company operating under the name Decoy Therapeutics. The deal is intended to accelerate the development of peptide conjugate therapeutics through Decoy’s IMP3ACT platform and integrate Salarius’ SP-3164 degrader program.Once complete, the combined company will be led by Decoy’s co-founders, Frederick Pierce and Barbara Hibner, alongside key executives from both firms. Over the next year, Decoy plans to push its lead antiviral drug for coronaviruses closer to FDA review, while also working on new treatments for flu, COVID-19, RSV, and certain gastrointestinal cancers.Salarius, meanwhile, is supporting a clinical study at MD Anderson Cancer Center that’s testing its main drug, seclidemstat, as a possible treatment for serious blood cancers with few existing options.On Stocktwits, retail sentiment for Salarius was ‘bullish’ amid a 5,000% surge in 24-hour message volume.One user said they had added to their Salarius position, citing the company’s low float, full Nasdaq compliance, and solid cash runway.&nbsp;<stembedurl>https://stocktwits.com/Rick2058/message/632179803</stembedurl>Another user noted they felt confident about the stock’s setup, pointing to its low price, small float, and high cost-to-borrow rate, adding that any positive news could send it soaring.<stembedurl>https://stocktwits.com/The_TendieMan_Cometh/message/632144546</stembedurl><a href="https://stocktwits.com/symbol/SLRX">Salarius’ stock</a> has declined 86% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Salarius’ stock (SLRX) has declined 86% so far in 2025. (Photo credit: Getty Images)

Salarius Pharma Stock Jumps After-Hours As Nasdaq Compliance Clears Path For Decoy Merger —  Retail Bulls Bet On Breakout

The company’s move removes the last major hurdle to completing its merger with Decoy Therapeutics, a deal aimed at advancing antiviral and cancer drug programs through Decoy’s IMP3ACT platform.

Equity

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.

Current Price	$0.6513
Prev Close	$0.6668
Open	$0.65
Dividend Yield	0.00%
50-Day Moving Average	$2.03
Beta	0.08
Avg. Volume	5.39M
PE Ratio	-0.02

52-Week High	$108.00
52-Week Low	$0.64
Market Capitalization	$3.91M
EPS (Annual)	-$86.92
Price to Book	0.15
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SLRX
Salarius Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLRX News

SLRXSalarius Pharmaceuticals Inc